CMB International Securities | Equity Research | Company Update

Mengniu (2319 HK)

2H20E guidance reaffirmed

MN reported 42% NP decline to RMB1,212mn in 1H20, beating its profit alert range of 45-60% decline on strong Jun sales and CMD results. Mgmt. maintained its 2H20E guidance of not less than low-teens revenue and 0.3-0.5ppt OPM expansion. 3Q20-to-date revenue growth was on track. Maintain Buy because growth momentum resumed to pre-epidemic period, evidenced by strong recovery in 2Q20. 3Q20-to-date revenue growth was on track. Our TP is lifted from HK\$37.90 to HK\$42.00, representing 28.0x FY21E P/E (vs 28.0x sum of 2HFY20E and 1HFY21E EPS previously).

- Strong recovery seen in 2Q20. Revenue fell 6% to RMB37,534mn in 1H20. If excluding Junlebao's disposal and Bellamy's acquisition in 2H19, organic revenue increased by 9% to RMB36,888mn in 1H20. In 1Q20, organic revenue growth was flat and MN recorded net loss of RMB127mn because of donation, extra expenses for marketing and epidemic-related. The business strongly recovered in 2Q20 with 19% organic revenue growth (channel restocking and more milk consumption to improve immunity) and 86% surge of NP on operating leverage (Figure 1).
- Focus on high-end products to improve margins. (1) Milk Deluxe: It achieved 19% growth in 1H20. It launched an upgraded version of 3.8g protein in May. Brand sales growth accelerated to 30%+ in 2Q20. High-margin "DreamCap" sales mix increased to 25% from high-teens in FY19. (2) Chilled fresh milk: Sales up 98% in 1H20 though Wuhan market was hit by COVID-19. High-margin "Shiny Meadow" sales mix rose 10ppt to 35%. (3) IMF: Yashili optimized its product portfolio in 1Q20 and focused on Reeborne new products. 2Q20 revenue +25% (vs -6% in 1H) with NPM improvement. Management targets 20-25% growth in 2H20E. Bellamy's launched super high-end organic cow and goat milk IMF in Australia in 2Q20 and launched Chinese version organic IMF this month. (4) Profitability of ice-cream and cheese increased significantly YoY in 1H20 due to improved product mix and products upgrade.
- Control selling expenses ratio. The Company will adopt build RTM strength (promote Smart Network system to distributors and channel penetration into town and villages), digitalization (facilitate precise communication with consumers) and consumer-centric full chain cost savings (product innovation and design led by consumer insights, cross-BU cost-cutting project team) to improve efficiency.
- Maintain Buy. We fine tuned our FY20/21/22E NP estimates by +2%/1%/1% as we raised FY20/21/22E revenue estimates by 3%/2%/2%. Catalysts: better-than-expected revenue and margins; Risks: slower-than-expected recovery and food safety issues.

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	68,977	79,030	76,734	86,875	97,263
YoY growth (%)	15	15	(3)	13	12
Net profit (RMB mn)	3,043	4,105	3,232	5,300	6,402
Adj. net profit (RMB mn)	2,942	3,867	3,232	5,300	6,402
Adjusted EPS (RMB)	0.754	0.988	0.821	1.346	1.626
YoY growth (%)	43	31	(17)	64	21
Consensus EPS (RMB)	na	na	0.847	1.270	1.522
Adjusted P/E (x)	39.8	32.2	38.8	23.7	19.6
P/B (x)	4.7	4.3	4.0	3.5	3.0
Yield (%)	0.6	0.6	0.6	1.0	1.2

Source: Company data, Bloomberg, CMBIS estimates



BUY (Maintain)

Target Price	HK\$42.00
(Previous TP	HK\$37.90)
Up/Downside	+18%
Current Price	HK\$30.80

China F&B Sector

Albert Yip (852) 3900 0838 albertyip@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	140,060
Avg 3 mths t/o (HK\$ mn)	372.94
52w High/Low (HK\$)	38.10/ 24.19
Total Issued Shares (mn)	3,935.0
Source: Bloomberg	

Shareholding Structure

COFCO	16.3%
Danone	9.9%
Arla	5.3%
Source: HKEx	

Share Performance

	AL L (
	Absolute	Relative
1-mth	5.2%	1.9%
3-mth	25.0%	14.7%
6-mth	28.3%	34.4%
Source: Bloomberg		

12-mth Price Performance



Source: Bloomberg

Auditor: EY

Related reports

- "Mengniu Profit warning removes 1. overhang; recovery ahead of guidance" – 10 Jun 2020 "Mengniu – Sales recovery ahead
- 2. of expectation" - 22 May 2020
- 3. "Mengniu - Resume double-digit revenue growth in 2H20E" - 27 Mar 2020
- 4. "Mengniu - Acquisition to access raw milk supply and become regional player" - 26 Nov 2019




Figure 1: 1H20 results review

	Comparable	business	%	Act	ual	%	
Y/E Dec (RMB mn)	1H20	1H19	change	1H20	1H19	change	Remarks
Revenue	36,888	33,714	9%	37,533	39,857	-6%	organic revenue +9% led by Milk Deluxe +19%, MN plain milk +25%, Fruit Milk Drink +11%. While UHT milk saw strong growth as consumers sought to increase immunity, UHT yogurt sales dropped
Cost of sales	(22,531)	(20,490)	10%	(22,881)	(24,279)	-6%	
Gross profit	14,357	13,224	9%	14,652	15,579	-6%	
Other income and gains	na	na	na	296	293	1%	
S&D expenses *	(11,500)	(9,533)	21%	(11,500)	(11,318)	2%	additional marketing expenses to destock channel inventory
Administrative expenses *	(1,439)	(1,367)	5%	(1,439)	(1,586)	-9%	
Other expenses	na	na	na	(1,054)	(664)	59%	donation exp jumped from RMB9mn to RMB446mn
Operating profit	na	na	na	956	2,304	-58%	
Finance income	na	na	na	564	511	10%	
Finance costs	na	na	na	(324)	(322)	1%	
Associates/JV	na	na	na	206	103	100%	China Modern Dairy NP +77%
Profit before tax	na	na	na	1,402	2,596	-46%	Around RMB1.8bn one-off and inventory destocking and epidemic-related expenses in 1H20
Tax expense	na	na	na	(268)	(435)	-39%	
Profit after tax	na	na	na	1,135	2,161	-47%	
Non-controlling interests	na	na	na	77	(84)	-192%	Junlebao business disposed in 2H19
Net profit	1,158	2,002	-42%	1,212	2,077	-42%	Junlebao contributed RMB77mn NP in 1H19; Bellamy's contributed RMB53mn NP in 1H20
Margin & Ratio (%)							
Gross margin	38.9	39.2	(0.3)	39.0	39.1	(0.1)	
Operating margin	na	na	na	2.5	5.8	(3.3)	
SG&A expenses ratio	35.1	32.3	2.8	34.5	32.4	2.1	
A&P expenses ratio	na	na	na	12.2	12.2	0.0	
Staff expenses ratio	na	na	na	7.9	8.6	(0.7)	
Net margin	3.1	5.9	(2.8)	3.2	5.2	(2.0)	
	1H20	1H19	change	1H20	1H19	change	
Inventory days	na	29	na	36	31	5	
A/C receivables days	na	18	na	19	17	2	
A/C payable days	na	55	na	59	59	0	

Source: Company data, CMBIS

Comparable business excluded Junlebao/Bellamy's businesses in 1H19/1H20 * 1H20 S&D and admin exp of comparable business included Bellamy's

Figure 2: Increasing market shares



Source: Nielsen



Figure 3: Retail price of Milk Deluxe (250mL*12) was RMB49.9 in a supermarket in Hunan in mid-Aug



Source: CMBIS



Figure 4: Retail price of Just Yoghurt original favour

(200g*12) was RMB46.8 in a supermarket in Hunan

Source: CMBIS

		New			Old		Diff (%)			
US\$ mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	
Revenue	76,734	86,875	97,263	74,513	85,337	95,293	3%	2%	2%	
Gross Profit	28,910	33,258	37,418	27,758	32,263	36,172	4%	3%	3%	
Operating Profit	3,202	5,370	6,447	3,182	5,418	6,521	1%	-1%	-1%	
Adjusted Net Profit	3,232	5,300	6,402	3,184	5,247	6,348	2%	1%	1%	
Gross Margin	37.7%	38.3%	38.5%	37.3%	37.8%	38.0%	+0.4ppt	+0.5ppt	+0.5ppt	
Operating Margin	4.2%	6.2%	6.6%	4.3%	6.3%	6.8%	-0.1ppt	-0.1ppt	-0.2ppt	
Adjusted Net Margin	4.2%	6.1%	6.6%	4.3%	6.1%	6.7%	-0.1ppt	flat	-0.1ppt	

Figure 5: Earnings revision

Source: Company data, CMBIS estimates


Figure 6: CMBIS estimates vs consensus

		CMBIS		(Consensus			Diff (%)	
US\$ mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	76,734	86,875	97,263	75,029	86,615	96,846	2%	0%	0%
Gross Profit	28,910	33,258	37,418	27,813	32,932	37,158	4%	1%	1%
Operating Profit	3,202	5,370	6,447	3,591	5,641	6,845	-11%	-5%	-6%
Adj. Net profit	3,232	5,300	6,402	3,282	4,952	5,947	-2%	7%	8%
Gross Margin	37.7%	38.3%	38.5%	37.1%	38.0%	38.4%	+0.6ppt	+0.3ppt	+0.1ppt
Operating Margin	4.2%	6.2%	6.6%	4.8%	6.5%	7.1%	-0.6ppt	-0.3ppt	-0.5ppt
Adj. Net Margin	4.2%	6.1%	6.6%	4.4%	5.7%	6.1%	-0.2ppt	+0.4ppt	+0.5ppt

Source: Bloomberg, CMBIS estimates



Figure 7: P/E band chart



Source: CMBIS estimates, Bloomberg, Company data



Financial Summary

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	68,977	79,030	76,734	86,875	97,263	Profit before tax	3,853	5,605	3,906	6,351	7,691
Liquid milk	59,389	67,878	68,102	76,949	86,093	Associates & JV	300	(175)	(296)	(385)	(493)
Ice-cream	2,723	2,561	2,613	2,743	2,798	D&A	1,838	2,260	1,779	1,972	2,108
Milk powder	6,017	7,870	5,119	6,013	6,851	Change in working capital	1,653	452	747	716	820
Others	848	721	900	1,170	1,521	Others	(1,280)	(1,835)	(1,811)	(2,243)	(2,607)
Cost of sales	(43,193)	(49,351)	(47,824)	(53,618)	(59,845)	Operating cash flow	6,363	6,307	4,325	6,411	7,519
Gross profit	25,784	29,679	28,910	33,258	37,418						
						Capex	(3,149)	(4,318)	(4,000)	(3,000)	(3,000)
Other income and gains	635	769	601	613	665	Acquisitions	(309)	(6,686)	(458)	0	0
Selling expenses	(18,833)	(21,536)	(21,639)	(23,934)	(26,553)	Others	(773)	(6,525)	2,519	(776)	(622)
Administration expenses	(2,915)	(3,319)	(3,223)	(3,649)	(4,085)	Investing cash flow	(4,232)	(17,530)	(1,939)	(3,776)	(3,622)
Other expenses	(936)	(1,482)	(1,448)	(918)	(998)						
EBIT	3,734	4,110	3,202	5,370	6,447	Change of borrowing	(383)	11,791	2,192	0	0
						Dividend paid	(526)	(1,374)	(712)	(743)	(1,219)
Finance income, net	318	461	438	627	781	Others	8	197	0	0	0
Others	101	860	0	0	0	Financing cash flow	(900)	10,614	1,480	(743)	(1,219)
JV & associates	(300)	184	296	385	493						
Pre-tax profit	3,853	5,615	3,936	6,381	7,721	Net change in cash	1,231	(608)	3,866	1,892	2,678
Income tax	(649)	(1,310)	(692)	(1,019)	(1,229)	Cash at the beginning	3,129	4,370	3,798	7,664	9,555
Less: Minority interests	(161)	(190)	17	(32)	(61)	Forex effect	10	36	0	0	0
Net profit	3,043	4,115	3,262	5,330	6,432	Cash at disposal groups	0	0	0	0	0
Adjusted net profit	2,942	3,867	3,232	5,300	6,402	Cash at the end	4,370	3,798	7,664	9,555	12,234
-						Time deposit	2,927	2,678	2,678	2,678	2,678
						Cash and cash equivalent	7,298	6,476	10,342	12,233	14,912

Balance sheet YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	Key ratios YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22F
Non-current assets	36,716	41,052	44,628	46,041	47,426	Sales mix (%)					
PPE	14,734	11,103	13,027	14,134	15,175	Liquid milk	86.1	85.9	88.8	88.6	88.5
Goodwill and intangible assets	6,980	12,302	12,235	12,168	12,101	lce-cream	3.9	3.2	3.4	3.2	2.9
JV & associates	7,202	7,492	8,246	8,631	9,124	Milk powder	8.7	10.0	6.7	6.9	7.0
Others	7,800	10,155	11,119	11,108	11,026	Others	1.2	0.9	1.2	1.3	1.6
Current assets	29,741	37,486	40,849	46,422	52,858	P&L ratios (%)					
Cash	7,298	6,476	10,342	12,233	14,912	Gross margin	37.4	37.6	37.7	38.3	38.5
Pledged deposit	623	74	74	74	74	EBIT margin	5.4	5.2	4.2	6.2	6.6
Inventory	4,282	5,090	5,741	6,437	7,184	Net margin	4.4	5.2	4.2	6.1	6.6
Trade receivables	2,892	3,587	4,046	4,580	5,128	Adjusted net margin	4.3	4.9	4.2	6.1	6.6
Others	14,646	22,259	20,646	23,097	25,559	Payout ratio	23.2	17.3	23.0	23.0	23.0
Current liabilities	25,109	31,734	31,156	33,553	36,130	Balance sheet ratios					
Borrowings	6,523	13,838	11,015	11,015	11,015	Current ratio (x)	1.2	1.2	1.3	1.4	1.5
Trade payables	7,022	6,739	7,601	8,522	9,511	A/C receivables days	15	15	18	18	18
Other payables	10,889	10,808	12,190	13,667	15,255	A/C payables days	56	51	55	55	55
Others	675	349	349	349	349	Inventory days	33	35	41	41	42
						Asset turnover (x)	1.0	1.0	0.9	0.9	1.0
Non-current liabilities	10,884	13,456	18,472	18,472	18,472	Net cash (RMB mn)	4,410	3,808	3,481	7,373	12,052
Borrowings	8,192	9,635	14,650	14,650	14,650						
Deferred revenue	856	279	279	279	279	Returns (%)					
Others	1,835	3,542	3,542	3,542	3,542	Adjusted ROE	12.3	14.2	10.6	15.6	16.5
						Adjusted ROA	4.7	5.3	3.9	6.0	6.6
Total net assets	30,464	33,347	35,849	40,438	45,682						
Shareholders' equity	25,212	29,132	31,652	36,208	41,391	Per share					
Non-controlling interests	5,252	4,215	4,198	4,230	4,291	EPS (RMB)	0.75	0.99	0.82	1.35	1.63
						DPS (RMB)	0.18	0.18	0.19	0.31	0.37
						BVPS (RMB)	6.42	7.40	8.04	9.20	10.52

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.